These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 11836178)

  • 21. [Rheumatoid arthritis and multiple myeloma--the risk of a combination of the 2 diseases].
    Lila AM; Mazurov VI; Novik AA
    Ter Arkh; 1997; 69(2):50-2. PubMed ID: 9173578
    [No Abstract]   [Full Text] [Related]  

  • 22. Kappa light chain myeloma with initial cutaneous involvement.
    Saka B; Erten N; Oztürk G; Yilmaz C; Dogan O; Buyukbabani N; Besisik SK
    Ann Hematol; 2006 Apr; 85(4):272-4. PubMed ID: 16425024
    [No Abstract]   [Full Text] [Related]  

  • 23. Chemotherapy of resistant multiple myeloma with vincristine, adriamycin and dexamethasone (VAD).
    Maniatis A; Stamatellou M; Papanastasiou K
    Chemioterapia; 1987 Jun; 6(2 Suppl):727-8. PubMed ID: 3509532
    [No Abstract]   [Full Text] [Related]  

  • 24. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial.
    Rifkin RM; Gregory SA; Mohrbacher A; Hussein MA
    Cancer; 2006 Feb; 106(4):848-58. PubMed ID: 16404741
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Multiple myeloma complicated with Takotsubo cardiomyopathy].
    Mitsumori T; Nakajima K; Nozaki Y; Hamanaka S; Nagashima T; Kirito K; Iwao N; Komatsu N
    Rinsho Ketsueki; 2010 Apr; 51(4):291-6. PubMed ID: 20467228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
    Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA
    Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Multiple myeloma of the IgD-lambda type invading CNS].
    Kitamura K; Takeuchi J; Kanbe E; Oka H; Saiki M; Aikawa S; Kura Y; Hatta Y; Yamazaki T; Ito T; Sawada U; Horie T
    Rinsho Ketsueki; 2004 Oct; 45(10):1124-8. PubMed ID: 15553049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma.
    Boccadoro M; Palumbo A; Bringhen S; Merletti F; Ciccone G; Richiardi L; Rus C; Bertola A; Giaccone L; Omedè P; Musto P
    Haematologica; 2002 Aug; 87(8):846-50. PubMed ID: 12161361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clonal evolution at leukemic relapse of multiple myeloma (secondary plasma cell leukemia) responding to re-treatment with bortezomib-based therapy. A case record.
    Bernardeschi P; Pirrotta MT; Montenora I; Giustarini G; Ferreri MI; Simi P; Fiorentini G
    Leuk Res; 2010 Apr; 34(4):e104-5. PubMed ID: 19889456
    [No Abstract]   [Full Text] [Related]  

  • 30. Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients.
    Kröger N; Damon L; Zander AR; Wandt H; Derigs G; Ferrante P; Demirer T; Rosti G; ; ;
    Bone Marrow Transplant; 2003 Dec; 32(12):1153-7. PubMed ID: 14647269
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term remission of paraprotein-induced immunotactoid glomerulopathy after high-dose therapy and autologous blood stem cell transplantation.
    Witzens-Harig M; Waldherr R; Beimler J; Zeier M; Hansmann J; Ho AD; Goldschmidt H; Moehler T
    Ann Hematol; 2007 Dec; 86(12):927-30. PubMed ID: 17605010
    [No Abstract]   [Full Text] [Related]  

  • 32. [Results of combined treatment of advanced forms of multiple myeloma with vincristine, melphalan, cyclophosphamide and prednisone (VMCP) and with vincristine, doxorubicin, cyclophosphamide and prednisone (VDCP)].
    Robak T; Krykowski E; Płuzańska A; Olszańska-Skorek T; Urbańska-Ryś H; Polkowska-Kulesza E; Błasińska-Morawiec M; Mazurowa A
    Pol Tyg Lek; 1983 Apr; 38(16):481-4. PubMed ID: 6579509
    [No Abstract]   [Full Text] [Related]  

  • 33. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone.
    Mellqvist UH; Lenhoff S; Johnsen HE; Hjorth M; Holmberg E; Juliusson G; Tangen JM; Westin J;
    Cancer; 2008 Jan; 112(1):129-35. PubMed ID: 17973267
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thalidomide for the treatment of leptomeningeal multiple myeloma.
    Yutaka H; Mariko Y; Shinichiro O; Kunihiko M; Yusuke T; Yasuo I
    Eur J Haematol; 2006 Apr; 76(4):358-9. PubMed ID: 16519710
    [No Abstract]   [Full Text] [Related]  

  • 35. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.
    Gobbi PG; Broglia C; Levis A; La Sala A; Valentino F; Chisesi T; Sacchi S; Corbella F; Cavanna L; Iannitto E; Pavone V; Molica S; Corazza GR; Federico M
    Clin Cancer Res; 2006 Jan; 12(2):529-35. PubMed ID: 16428496
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.
    Cavo M; Benni M; Ronconi S; Fiacchini M; Gozzetti A; Zamagni E; Cellini C; Tosi P; Baccarani M; Tura S;
    Haematologica; 2002 Sep; 87(9):934-42. PubMed ID: 12217805
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Multiple myeloma and acute leukemia. Simultaneous evolution of plasmacyte and myelomonocytic clones].
    Renoux M; Bernard JF; Bezeau A; Amar M; Boivin P
    Sem Hop; 1978 Sep 18-25; 54(25-28):809-13. PubMed ID: 214859
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation.
    Rawstron AC; Davies FE; DasGupta R; Ashcroft AJ; Patmore R; Drayson MT; Owen RG; Jack AS; Child JA; Morgan GJ
    Blood; 2002 Nov; 100(9):3095-100. PubMed ID: 12384404
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients.
    Hussein MA; Wood L; Hsi E; Srkalovic G; Karam M; Elson P; Bukowski RM
    Cancer; 2002 Nov; 95(10):2160-8. PubMed ID: 12412170
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
    Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V
    Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.